CSU vs. Inducible Urticaria: Distinguishing Spontaneous from Triggered Disease

Dr. Chovatiya invites the panel to distinguish CSU from chronic inducible urticaria (CIndU) and acute urticaria. Dr. Hawkes explains that all chronic urticaria begins as acute urticaria that simply hasn't resolved, typically within one to two weeks in 80–90% of cases and most commonly in younger patients. The key differentiator for chronic urticaria is frequency: CSU patients have symptoms most days, whereas CIndU patients may have symptom-free gaps when they avoid their specific trigger. If a patient says their hives are "pretty much every day," that nearly always points to a spontaneous rather than inducible process. He also notes that approximately 30% of patients have an overlap of both spontaneous and inducible components, and in those cases, he focuses on identifying the predominant pattern.

Dr. Friedman adds an important caution: dermatographia (symptomatic dermographism) is the most common inducible urticaria, and he has seen clinicians miss a concurrent CSU diagnosis by attributing everything to the inducible trigger. Patients can—and do—have both. He recommends actively testing for inducible subtypes in the office by performing a dermographism scratch test (without breaking the skin), running a cold stimulus test, or having the patient do jumping jacks to check for cholinergic urticaria. The more inducible subtypes present alongside CSU, the harder the overall disease may be to treat. Knowing the full picture doesn't necessarily change the treatment ladder, but it informs prognosis and helps set expectations.

The panel weaves in a broader disease context: CSU is twice as common in women, and it is associated with an increased risk of autoimmune conditions. A patient with a personal or family history of celiac disease, lupus, or rheumatoid arthritis fits the CSU patient profile. Understanding this autoimmune backdrop helps move patients away from the frustrating search for a dietary or environmental cause, and toward a more useful framing: comorbid conditions run in parallel with CSU, but addressing one does not eliminate the other.

In the next episode, "Stepping Up Treatment: Antihistamines, Guidelines, and When to Escalate in CSU," the panel turns to treatment strategy—discussing appropriate antihistamine use, dose escalation, and when to move to advanced therapies.